scholarly journals Organised screening for cervical cancer in France: a cost-effectiveness assessment

BMJ Open ◽  
2017 ◽  
Vol 7 (10) ◽  
pp. e014626 ◽  
Author(s):  
Stéphanie Barré ◽  
Marc Massetti ◽  
Henri Leleu ◽  
Frédéric De Bels
Keyword(s):  
Cervical Cancer ◽  
Cost Effectiveness ◽  
Cost Saving ◽  
Pap Test ◽  
Participation Rate ◽  
Screening Tests ◽  
Lifetime Horizon ◽  
Effective Strategies ◽  
Hpv Test ◽  
Effectiveness Assessment

ObjectiveAccording to the third cancer plan, organised screening (OS) of cervical cancer (CC) among women aged 25–65 years should be implemented in France in the forthcoming years. The most efficient way to implement OS in the French healthcare system is yet to be determined.MethodsA microsimulation model was developed adopting a collective ‘all payers’ perspective. A closed cohort of women eligible for CC screening and representative in terms of age and participation in individual screening (IndScr) by annual Papanicolaou (Pap) testing every 3 years was modelled on a lifetime horizon. Different OS strategies, additive to IndScr with a 61.9% participation rate based on mailed invitations to non-participant women to perform OS were assessed. Similar modalities were applied to OS and IndScr participants. Strategies implied different screening tests (Papanicolaou (Pap) test, human papillomavirus (HPV) test and p16/Ki67 double staining) and OS periodicity.ResultsCompared with IndScr only, all OS strategies were associated with decreased cancer incidence/mortality (from 14.2%/13.5% to 22.9%/25.8%). Most strategies generated extra costs ranging from €37.9 to €1607 per eligible woman. HPV testing every 10 and 5 years were cost saving. HPV tests every 10 and 5 years were the most efficient strategies, generating more survival at lower costs than Pap-based strategies. Compared to IndScr only, an HPV test every 10 years was cost saving. The most effective strategies were p16/Ki67 as primary or HPV positive confirmation tests, with respective incremental cost-effectiveness ratios of €6 541 250 and €101 391 per life year. Pap-based strategies generated intermediary results.ConclusionOS strategies based on the HPV test appear highly efficient. However, our results rely on the assumption that women and practitioners comply with the recommended OS periodicities (3, 5, 10 years). Implementing these OS modalities will require major adaptations to the current CC screening organisation. Pap test-based strategies might be simpler to setup while preparing an appropriate implementation of more efficient OS screening modalities.

PP62 Cost-Effectiveness Of Cervical Cancer Screening In Estonia

2019 ◽  
Vol 35 (S1) ◽  
pp. 49-49
Author(s):  
Triin Võrno ◽  
Kaja-Triin Laisaar ◽  
Terje Raud ◽  
Kai Jõers ◽  
Doris Meigas-Tohver ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cost Effectiveness ◽  
Cancer Screening ◽  
Cervical Cancer Screening ◽  
Screening Program ◽  
Pap Test ◽  
Cancer Screening Program ◽  
Hpv Test ◽  
Cervical Cancer Screening Program ◽  
The Cost

IntroductionIn Estonia, organized cervical cancer screening program is targeted at women aged 30–55(59) years and Pap-tests are taken every five years. Since cervical cancer is associated with human papillomavirus (HPV), a number of countries have introduced the HPV-test as the primary method of screening. The objective of this study was to evaluate the cost-effectiveness of organized cervical cancer screening program in Estonia by comparing HPV- and Pap-test based strategies.MethodsFor the cost-effectiveness analysis, a Markov cohort model was developed. The model was used to estimate costs and quality-adjusted life-years (QALYs) of eight screening strategies, varying the primary screening test and triage scenarios, upper age limit of screening, and testing interval. Incremental cost-effectiveness ratios (ICERs) were calculated in comparison to current screening practice as well as to the next best option. Sensitivity analysis was performed by varying one or more similar parameter(s) at a time, while holding others at their base case value. The analysis was performed from the healthcare payer perspective adopting a five percent annual discount rate for both costs and utilities.ResultsIn the base-case scenario, ICER for HPV-test based strategies in comparison to the current screening practice was estimated at EUR 8,596–9,786 per QALY. For alternative Pap-test based strategies ICER was estimated at EUR 2,332–2,425 per QALY. In comparison to the next best option, HPV-test based strategies were dominated by Pap-test based strategies. At the cost-effectiveness threshold of EUR 10,000 per QALY Pap-testing every three years would be the cost-effective strategy for women participating in the screening program from age 30 to 63 (ICER being EUR 3,112 per QALY).ConclusionsDecreasing Pap-test based screening interval or changing to HPV-test based screening can both improve the effectiveness of cervical cancer screening program in Estonia, but based on the current cost-effectiveness study Pap-test based screening every three years should be preferred.

scholarly journals Cost-effectiveness of zoledronic acid compared with sequential denosumab/alendronate for older osteoporotic women in Japan

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Takahiro Mori ◽  
Carolyn J. Crandall ◽  
Tomoko Fujii ◽  
David A. Ganz
Keyword(s):  
Health Economic ◽  
Cost Effectiveness ◽  
Zoledronic Acid ◽  
Cost Saving ◽  
Fragility Fracture ◽  
Community Dwelling ◽  
Sensitivity Analyses ◽  
Term Care ◽  
Lifetime Horizon ◽  
The Cost

Abstract Summary Among hypothetical cohorts of older osteoporotic women without prior fragility fracture in Japan, we evaluated the cost-effectiveness of two treatment strategies using a simulation model. Annual intravenous zoledronic acid for 3 years was cost-saving compared with biannual subcutaneous denosumab for 3 years followed by weekly oral alendronate for 3 years. Purpose Osteoporosis constitutes a major medical and health economic burden to society worldwide. Injectable treatments for osteoporosis require less frequent administration than oral treatments and therefore have higher persistence and adherence with treatment, which could explain better efficacy for fracture prevention. Although annual intravenous zoledronic acid and biannual subcutaneous denosumab are available, it remains unclear which treatment strategy represents a better value from a health economic perspective. Accordingly, we examined the cost-effectiveness of zoledronic acid for 3 years compared with sequential denosumab/alendronate (i.e., denosumab for 3 years followed by oral weekly alendronate for 3 years, making the total treatment duration 6 years) among hypothetical cohorts of community-dwelling osteoporotic women without prior fragility fracture in Japan at ages 65, 70, 75, or 80 years. Methods Using a previously validated and updated Markov microsimulation model, we obtained incremental cost-effectiveness ratios (Japanese yen [¥] (or US dollars [$]) per quality-adjusted life-year [QALY]) from the public healthcare and long-term care payer’s perspective over a lifetime horizon with a willingness-to-pay of ¥5 million (or $47,500) per QALY. Results In the base case, zoledronic acid was cost-saving (i.e., more effective and less expensive) compared with sequential denosumab/alendronate. In deterministic sensitivity analyses, results were sensitive to changes in the efficacy of zoledronic acid or the cumulative persistence rate with zoledronic acid or denosumab. In probabilistic sensitivity analyses, the probabilities of zoledronic acid being cost-effective were 98–100%. Conclusions Among older osteoporotic women without prior fragility fracture in Japan, zoledronic acid was cost-saving compared with sequential denosumab/alendronate.

scholarly journals Economic Evaluation of Posaconazole Versus Standard Azole Therapy as Prophylaxis against Invasive Fungal Infections in Patients with Prolonged Neutropenia in Canada

2012 ◽  
Vol 23 (2) ◽  
pp. 59-64 ◽  
Author(s):  
Amir A Tahami Monfared ◽  
Amy K O’Sullivan ◽  
Coleman Rotstein ◽  
George Papadopoulos
Keyword(s):  
Cost Effectiveness ◽  
High Risk ◽  
Cost Saving ◽  
Incremental Cost ◽  
Incremental Cost Effectiveness Ratio ◽  
Cost Effectiveness Ratio ◽  
Lifetime Horizon ◽  
System Perspective ◽  
Life Years ◽  
Neutropenic Patients

INTRODUCTION: Posaconazole prophylaxis in high-risk neutropenic patients prevents invasive fungal infection (IFI). An economic model was used to assess the cost effectiveness of posaconazole from a Canadian health care system perspective.METHODS: A decision-analytic model was developed based on data from a randomized trial comparing posaconazole with standard azole (fluconazole or itraconazole) therapy. The model was extrapolated to a lifetime horizon using one-month Markov cycles; lifetime survival was specific to the underlying disease. Drug and treatment costs associated with IFI were estimated using published literature. The model was used to estimate total costs, IFIs avoided, life-years gained and the incremental cost-effectiveness ratio of posaconazole versus standard azole therapy, in 2007 Canadian dollars.RESULTS: Based on the clinical trial data, posaconazole was associated with fewer cases of IFI (0.05 versus 0.11; P=0.003), increased life-years (2.52 years versus 2.43 years) and slightly lower costs ($6,601 versus $7,045) per patient relative to standard azole therapy over a lifetime horizon. Higher acquisition costs for posaconazole were offset by IFI-associated inpatient costs for those prophylaxed with standard azoles. Probabilistic sensitivity analysis indicated a 59% probability that posaconazole was cost-saving versus standard azole therapy and a 96% probability that the incremental cost-effectiveness ratio for posaconazole was at or below the $50,000 per life-year saved threshold.DISCUSSION: In Canada, posaconazole appears to be cost-saving relative to standard azole therapy in IFI prevention among high-risk neutropenic patients.

scholarly journals Breakthroughs and Issues in HPV Genital Infections in relation to Cervical Cancer

2012 ◽  
Vol 1 (2) ◽  
pp. 27-30
Author(s):  
Farhat Hussain ◽  
Khairun Nahar ◽  
Kaniz Fatema ◽  
Mahbuba Khan
Keyword(s):  
Cervical Cancer ◽  
Pap Smear ◽  
Pap Test ◽  
Cervical Cancer Prevention ◽  
Cervical Lesions ◽  
Related Condition ◽  
Papilloma Virus ◽  
Medical College ◽  
Hpv Test ◽  
Neoplastic Process

The field of cervical cancer prevention is rapidly evolving because of identification of the cause of disease. Human Papilloma Virus (HPV) has been recognized as a necessary cause of cervical cancer, and the association applies equally to both squamous cell and adenocarcinoma and is consistent worldwide. HPV 16 and 18 together attribute 70% of world's cervical cancer. HPV is highly prevalent among sexually active women and traceable in its natural history with technology that can detect HPV DMA at all stages of infection and neoplastic process. HPV DMA testing represents the scientifically obvious next step after Pap test for secondary prevention. A clinically validated and FDA approved HPV test has proven a substantial gain in sensitivity with a limited loss in speciality as compared to the standard Pap smear. We are now in the fortunate position of having two highly promising HPV vaccines in the pipeline. These vaccines today represent new hope for protection against cervical cancer, pre-cancerous cervical lesions and other HPV related condition for the current generation of adolescents, for the young and middle aged women as well as for the future generations. DOI: http://dx.doi.org/10.3329/jssmc.v1i2.12163 Journal of Shaheed Suhrawardy Medical College Vol.1, No.2, December 2009 p.27-30

Dynamics of Human Papillomavirus and Cervical Cancer Screening

2011 ◽  
Vol 07 (04) ◽  
pp. 243
Author(s):  
Channa E Schmeink ◽  
Leon FAG Massuger ◽  
Willem JG Melchers ◽  
Ruud LM Bekkers ◽  
◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Cancer Screening ◽  
Cervical Cancer Screening ◽  
Cervical Carcinoma ◽  
Participation Rate ◽  
Productive Infection ◽  
High Grade ◽  
Screening Guidelines ◽  
Hpv Test

Primary screening based on detection of human papillomavirus (HPV) has proved to be more sensitive than cytology for the detection of high-grade cervical intraepithelial neoplasia (CIN). Self-sampling for specimen collection may also improve the participation rate, especially in the non-responder group. However, HPV is highly prevalent and therefore HPV detection has a lower specificity in cervical cancer screening than cytology. In addition to the clinically validated HPV test, HPV dynamics should be taken into account. It is important to identify women with a chronic productive infection likely to cause, or to already have caused, high-grade CIN or cervical carcinoma, and to limit overtreatment of women with a transient infection. Furthermore, the introduction of the HPV vaccine is likely to lower the incidence of CIN and cervical carcinoma, which will lower the positive predictive value of cervical cancer screening. This potential impact needs to be taken into account when planning for future screening guidelines.

scholarly journals Patterns and Trends of Cancer Screening in Canada: Results From a Contemporary National Survey

2021 ◽  
Vol 19 (1) ◽  
pp. 68-76
Author(s):  
Omar Abdel-Rahman
Keyword(s):  
Breast Cancer ◽  
Cervical Cancer ◽  
Cancer Screening ◽  
Cervical Cancer Screening ◽  
Pap Test ◽  
Complete Information ◽  
Screening Tests ◽  
Visible Minority ◽  
Crc Screening ◽  
Breast And Cervical Cancer

Background: The aim of this study was to assess the patterns and trends of colorectal, breast, and cervical cancer screening within a contemporary cohort of Canadian adults. Methods: Canadian Community Health Survey datasets (2007–2016) were accessed and 3 cohorts were defined: (1) a colorectal cancer (CRC) screening cohort, defined as men and women aged 50 to 74 years with complete information about CRC screening tests and their timing; (2) a breast cancer screening cohort, defined as women aged 40 to 74 years with complete information about mammography and its timing; and (3) a cervical cancer screening cohort, defined as women aged 25 to 69 years with complete information about the Papanicolaou (Pap) test and its timing. Multivariable logistic regression analysis was then performed to evaluate factors associated with not having timely screening tests at the time of survey completion. Results: A total of 99,820 participants were considered eligible for the CRC screening cohort, 59,724 for the breast cancer screening cohort, and 46,767 for the cervical cancer screening cohort. Among eligible participants, 43% did not have timely recommended screening tests for CRC, 35% did not have timely mammography (this number decreased to 26% when limiting the eligible group to ages 50–74 years), and 25% did not have a timely Pap test. Lower income was associated with not having a timely recommended screening tests for all 3 cohorts (odds ratios [95% CI]: 1.86 [1.76–1.97], 1.89 [1.76–2.04], and 1.96 [1.79–2.14], respectively). Likewise, persons self-identifying as a visible minority were less likely to have timely recommended screening tests in all 3 cohorts (odds ratios for White race vs visible minority [95% CI]: 0.87 [0.83–0.92], 0.85 [0.80–0.91], and 0.66 [0.61–0.70], respectively). Conclusions: More than one-third of eligible individuals are missing timely screening tests for CRC. Moreover, at least one-quarter of eligible women are missing their recommended breast and cervical cancer screening tests. More efforts from federal and provincial health authorities are needed to deal with socioeconomic disparities in access to cancer screening.

scholarly journals Self-Collected Samples in Cervical Cancer Screening: Results of HPV and Pap Self-Collected Samples Compared to Physician-Obtained Specimens

2019 ◽  
Vol 63 (5) ◽  
pp. 379-384
Author(s):  
Bernhard Reinhold Mangold
Keyword(s):  
Cervical Cancer ◽  
Cancer Screening ◽  
Positive Predictive Value ◽  
Predictive Value ◽  
Pap Test ◽  
Pap Tests ◽  
Test Sensitivity ◽  
Self Testing ◽  
Hpv Test ◽  
Very High

Objective: In order to increase overall participation in cervical cancer screening, several investigators propose a concept of introducing self-tests. The study presented here compared test results of the Pap test and 4 different HPV test systems of self-collected and physician-collected vaginal specimens. Study Design: 208 patients of a colposcopy clinic had physician-taken and self-taken vaginal samples. All cell samples enabled a liquid-based Pap test and testing for carcinogenic HPV genotypes. In addition, all patients had a colposcopy with or without cervical biopsy and/or conisation. Results: 99 patients had the histological diagnosis of CIN2+. The HPV test sensitivity of self-collected samples differed significantly in this patient group depending on the test system performed. The sensitivity of the self-collected Pap test was significantly lower than HPV testing, but the positive predictive value of the Pap self-test was very high. Conclusion: The results of this study indicate that under the circumstances of self-testing HPV test systems differ in test sensitivity and specificity. Self-collected Pap tests can provide a test result with a very high positive predictive value and introduce therapeutic strategies. In order to improve screening strategies, it could be an opportunity to combine HPV and Pap tests in self-taken vaginal samples, especially in countries with a low income level. In countries with a good medical infrastructure, self-testing has to be introduced with caution.

scholarly journals Genetic Screening of Cervical Cancer

OBM Genetics ◽  
2021 ◽  
Vol 05 (03) ◽  
pp. 1-1
Author(s):  
Ciro Comparetto ◽  
◽  
Franco Borruto ◽  
Keyword(s):  
Cervical Cancer ◽  
Molecular Biology ◽  
Pap Smear ◽  
Pap Test ◽  
Prevention Programs ◽  
Small Sample ◽  
Screening Programs ◽  
Pap Smear Screening ◽  
Hpv Test ◽  
Screening And Prevention

Medical genetics plays an important role in the screening and prevention of numerous diseases. Thus, it is important to develop effective screening and prevention programs and improve the assessment of the susceptibility of diseases. The development of screening and prevention programs depends on the identification of early biomarkers (including functional and behavioral) for the risk and onset of the disease, and such programs need to be designed according to internationally accepted criteria. Cervical cancer represents a very relevant disease from the health and social perspective; around 528,000 new cases are diagnosed every year globally, of which, 85% are from developing countries, representing almost 12% of all cancers in females. Substantial reductions in the incidence of and mortality from cervical cancer have been observed after the introduction of prevention campaigns with the implementation of cervical screening programs through Papanicolaou (Pap) tests and, in particular, following the introduction of organized programs which guarantee a high level of screening coverage, as well as, the quality and continuity of diagnostic-therapeutic procedures. It is estimated that Pap smear screening every 3-5 years provides 80% protection against the onset of cancer. Advances in diagnostic techniques, particularly the development of easy-to-use molecular genetic tests, are replacing the use of the established Pap smear as a screening tool. This is possible owing to the discovery in 1975 that some cellular morphological changes (koilocytosis) were related to the presence of a Human Papillomavirus (HPV) infection. The HPV test is performed on a small sample of cells taken from the cervix, similar to the Pap test; however, it is not a morphological exam but a molecular biology exam that detects the presence of HPV by identifying its deoxyribonucleic acid (DNA) or messenger ribonucleic acid (mRNA). The results of numerous experimental studies have demonstrated a greater sensitivity of this test compared to the sensitivity of the traditional Pap test. However, the HPV test has a lower specificity due to two main factors: 1) The HPV test is based on the search for the types of viruses that have a greater oncogenic potential, and 2) It does not discriminate between transient infections and persistent and productive infections. The most widely used molecular tests are based on the search for HPV sequences and genotyping using molecular biology techniques, such as direct hybridization, qualitative polymerase chain reaction (PCR), and viral nucleotide sequencing.

scholarly journals Cost-Effectiveness of Smoking Cessation Within a Lung Cancer Screening Program in Canada

2018 ◽  
Vol 4 (Supplement 2) ◽  
pp. 41s-41s ◽  
Author(s):  
C. Gauvreau ◽  
N. Fitzgerald ◽  
W. Flanagan ◽  
S. Memon ◽  
J. Goffin ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Smoking Cessation ◽  
Cost Effectiveness ◽  
Cancer Screening ◽  
Screening Program ◽  
Lung Cancer Screening ◽  
Participation Rate ◽  
Lifetime Horizon ◽  
Quit Rate ◽  
Low Dose Computed Tomography

Background: Demonstrated lung cancer mortality reductions through low-dose computed tomography (LDCT) has encouraged some jurisdictions to consider implementing organized LDCT screening. A retrospective analysis of former smokers in the National Lung Screening Trial (NLST) suggested that abstention from smoking coupled with low-dose computed tomography (LDCT) screening realized more mortality benefits than abstinence alone or LDCT alone. Aim: We evaluated the potential costs and cost-effectiveness of lung cancer screening with integrated smoking cessation using OncoSim-Lung (version 2.5), a microsimulation model led by the Canadian Partnership Against Cancer, with model development by Statistics Canada. Methods: We compared organized LDCT screening without smoking cessation to various plausible scenarios of screening with cessation. Assumptions included: annual screening of 55-74 year-old individuals with a 30-pack-yr history; a 42% participation rate reached over 10 years; cessation therapy (nicotine replacement therapy + varenicline + 12 weeks' counseling) at a cost of $490; and up to 10 cessation attempts, with a permanent quit rate of 5% per attempt. Cost-effectiveness was estimated with a lifetime horizon, health system perspective and 1.5% discount rate. Costs are in 2016 CAD. Results: OncoSim-Lung projected that LDCT screening integrated with cessation would cost approximately $76 million annually (undiscounted) from 2017 to 2036 in Canada. About 110 fewer lung cancer (LC) cases and 50 fewer LC deaths would occur annually, compared with screening without cessation. Additionally, many other smoking-related deaths would be prevented. Using a lifetime horizon, smoking cessation would cost $14,000/QALYs gained. In one-way sensitivity analysis, with a 72% participation rate there would be 260 fewer deaths, at $24,000/QALY. With a 10% quit rate, cost-effectiveness would improve to $6,000/QALY. A 50% increase in the cost of the cessation intervention would decrease cost-effectiveness to $22,000/QALY. Conclusion: Robust smoking cessation efforts within a LDCT screening program could save lives and be relatively cost-effective. Cancer control planners should consider integrating smoking cessation when implementing a lung cancer screening initiative.

scholarly journals Caracterização socioepidemiológica da população acometida pelo HPV e as dificuldades no manejo da doença / Socio-epidemiological characterization of the population affected by HPV and the difficulties in managing the disease

2021 ◽  
Vol 66 (1u) ◽  
pp. 1
Author(s):  
Érika Ferreira Marrara
Keyword(s):  
Cervical Cancer ◽  
Sex Education ◽  
Pap Smear ◽  
Scientific Data ◽  
Screening Tests ◽  
Indirect Contact ◽  
Public Network ◽  
Family Approach ◽  
Hpv Test ◽  
Management Of Hpv

Introdução: O papiloma vírus humano, ou HPV, é um vírus que infecta pele ou mucosa, transmitido por meio do contato direto, ou indireto com a área afetada. Esta infecção em sua maioria regride, porém, em seu pequeno número de casos, onde persiste, podem progredir para o câncer de colo do útero. O câncer de colo uterino é prevenível com associação a vacina e a realização de exames preventivos de rotina que detectam a lesão precursora. Objetivo: Realizar a análise socioepidemiológica do HPV, avaliar o perfil da população acometida pela doença e identificar os impactos no manejo da doença para entender como reduzir os números de casos. Materiais e métodos: O presente estudo se deu de modo descritivo realizado através de consultas de dados de bases científicas. Resultados: A técnica de citologia oncótica, como forma de rastreio do HPV e prevenção ao câncer de colo do útero, apresentou diversas limitações, como baixa a moderada sensibilidade, baixa reprodutibilidade e grande número de falso-negativos. O rastreio do HPV por PCR em tempo real apresentou-se como o método mais eficaz no diagnóstico do HPV por apresentar maior sensibilidade e eficiência para o rastreio. A educação sexual mostrou-se indispensável tanto para informações a respeito da doença, quanto para a prevenção. Discussão: São necessários investimentos no desenvolvimento de práticas para a promoção da saúde, além da campanha realizada atualmente para vacinação contra HPV, é preciso associar a campanhas de uso de preservativo e campanhas de incentivo a realização de exames de rastreamento, além da inclusão de educação sexual em escolas e abordagem pela família. Assim é possível conscientizar a população, refletindo diretamente na redução da contaminação. Conclusão: O teste de rastreamento disponibilizado na rede pública e o acesso à informação sobre medidas de prevenção se mostraram como fatores que dificultam o manejo do HPV. Ainda com todas as informações levantadas, são necessárias mais avaliações para que assim projetos mais efetivos sejam implementados para o controle do HPV.Palavras chave: HPV, Câncer de colo do útero, Teste de Papanicolaou, HPV, PCR, PapanicolaouABSTRACTIntroduction: Human papilloma virus, or HPV, is a virus that infects the skin or mucosa, transmitted through direct or indirect contact with the affected area. This infection mostly regresses, however, in its small number of cases, where it persists, it can progress to cervical cancer in women. Cervical cancer is preventable in combination with the vaccine and routine preventive examinations that detect the precursor lesion. Objective: Perform the socio-epidemiological analysis of HPV, evaluate the profile of the population affected by the disease and identify the impacts on the management of the disease for understand how to reduce number of cases. Materials and methods: The present study was carried out in a descriptive way, carried out through scientific data consultations. Results: The oncotic cytology technique, as a way of screening HPV and preventing cervical cancer, presented several limitations, such as low to moderate sensitivity, low reproducibility and a large number of false negatives. HPV screening by real-time PCR was shown to be the most effective method for diagnosing HPV because it has greater sensitivity and efficiency for screening. Sex education proved to be indispensable both for information about the disease and for prevention. Discussion: Investments are needed in the development of practices for health promotion, in addition to the campaign currently carried out for vaccination against HPV, it is necessary to associate it with campaigns of condom use and campaigns to encourage the performance of screening tests, in addition to the inclusion of sexual education in schools and family approach. Thus it is possible to raise awareness among the population, directly reflecting on the reduction of contamination. Conclusion: The screening test made available on the public network and access to information on preventive measures proved to be factors that hinder the management of HPV. Even with all the information collected, more evaluations are necessary so that more effective projects are implemented for the control of HPV.Keywords: HVP, Cervical cancer, HPV Test, PCR, PAP smear

Sign in / Sign up

Export Citation Format

Share Document